Pharmaceutical

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60…

9 months ago

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Phenotypic Characterization of ENPP1 Deficiency JBMR image of the phenotypic characterization of ENPP1 Deficiency - Data from the largest retrospective…

9 months ago

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the…

9 months ago

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

9 months ago

Evaxion to present at World Vaccine Congress

Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX)…

9 months ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over…

9 months ago

Avalyn to Participate in Upcoming Investor Conference in April

CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled…

9 months ago

Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors

Dr. Roger Dansey Dr. Roger Dansey joins Ottimo Pharma Limited Board of Directors Dansey, a former senior executive at Pfizer…

9 months ago

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

A$5.0 million commitment received from Australian-based private investorA$10.8 million Entitlement Offer at the same offer price as the placementFunds to…

9 months ago

BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of…

9 months ago